GLP-1 / metabolic

Dulaglutide

FDA-approved

Trulicity · GLP-1 receptor agonist (Fc-fusion)

Convenient once-weekly GLP-1 agonist for type 2 diabetes.

Half-life

~5 days (weekly)

Route

Subcutaneous weekly

Evidence

FDA-approved — T2D and CV risk reduction in T2D.

What it is

A GLP-1 analog fused to an antibody Fc fragment for extended half-life, delivered by pre-filled auto-injector.

How it works

GLP-1 agonism boosts glucose-dependent insulin, suppresses glucagon, slows gastric emptying and reduces appetite.

Studied for

Glycemic control and CV risk reduction (REWIND); modest weight loss.

Regulatory status

FDA-approved drug.

Safety

GI effects common; boxed thyroid C-cell tumor warning; pancreatitis and gallbladder cautions.

Reconstitution calculator →

Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.